Quinapril Hydrochloride Tablets

This product is a non-sulfhydryl, long-acting, oral angiotensin converting enzyme (ACE) inhibitor. After oral administration, it is hydrolyzed in the liver into an active diacid compound, namely quinaprilat, which can inhibit ACE and prevent angiotensin I from converting to angiotensin II, thereby significantly weakening the vasoconstriction mediated by angiotensin II and reducing arterial vascular resistance; it also inhibits the synthesis of aldosterone, reduces the retention of water and sodium produced by aldosterone, and further reduces blood pressure. Therefore, it is a safe and efficient antihypertensive drug.

The main ingredient of this product is S-2[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-1,2,3,4-tetrahydro-3-isoquinolinate

This product is a brown film-coated tablet.

It is suitable for patients with hypertension and congestive heart failure who are not satisfied with the effects of conventional drug treatment or have more adverse reactions. In the former, the efficacy of this product is equivalent to that of enalapril and better than that of captopril; in the latter, after long-term use, the effect of this product remains unchanged and can significantly improve symptoms and increase exercise capacity.

The absorption of this product after oral administration is not affected by food. The recommended starting dose for mild to moderate hypertension is 10 mg per day, once a day. If the antihypertensive effect is not satisfactory, it can be increased to 20-30 mg per day. The maximum dose is 40 mg per day, taken once a day or twice a day. The maintenance dose is generally 10 mg per day. The increment of this product usually takes 1 to 2 weeks. For patients who have taken diuretics, the starting dose should be halved. For patients with severe hypertension and those who are still dissatisfied with the drop in blood pressure after drug increments, a small dose of diuretics (such as thiazides) or calcium antagonists can be added. For patients with congestive heart failure, on the basis of the treatment with diuretics and cardiac glycosides, the recommended starting dose of this product is 5 mg/day. Pay attention to monitor whether the patient has symptomatic hypotension. The dose can be gradually increased to 10-20 mg each time, twice a day.

It is basically the same as other angiotensin converting enzyme inhibitors, but it is milder and has a lower incidence. The main symptoms are angioedema, hypotension, dizziness, headache, fatigue, rhinitis, nausea, vomiting, cough, abdominal pain, increased blood creatinine and urea nitrogen, etc. Patients with severe renal function impairment may cause neutropenia and agranulocytosis. This product is not easy to pass through the blood-brain barrier, and central adverse reactions are rare. Similar to other ACE inhibitors, it can cause dry cough and rarely cause angioedema. For patients with renal artery stenosis, it can cause renal failure.

Pregnant women and those who are allergic to this drug are prohibited from using it. All ACE inhibitors will reduce the secretion of aldosterone and enhance the sodium excretion and potassium conservation effect. When patients with renal insufficiency, diabetic patients with mild renal insufficiency, and patients taking potassium supplements or potassium-sparing diuretics (such as spironolactone, triamterene or amiloride) take this product, hyperkalemia will occur.

Precautions for children: Not clear yet Precautions for pregnancy and lactation: Not allowed for pregnant women Precautions for the elderly: See [Precautions]

Combination with diuretics and/or beta-receptor blockers can enhance the antihypertensive effect and improve the antihypertensive efficacy. This product contains magnesium carbonate, which can reduce the absorption of tetracycline antibiotics. All ACE inhibitors will reduce the excretion of lithium through the kidneys.

Keep in a light-proof and airtight container.

10mg

24 months

Harbin Pharmaceutical Group Co., Ltd. GENERAL Pharm. FACTORY

• Founded in:

  1994-05-19

• Address:

  No. 388, Hahei Highway, Hulan District (production base No. 109, Xuefu Road, Nangang District, No. 1, Junmin Street, Xiangfang District)

• Tax NO.:

  912301008280277137

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view